Skip to main content

Table 1 Relationship between clinicopathological features and tumor biomarkers in ESCC

From: Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma

Variable

CA19–9 (U/ml)

CA72–4 (U/ml)

CEA (ug/L)

Cyfra21–1 (ng/ml)

SCC-Ag (ng/ml)

< 37(%)

≥37(%)

p

< 6(%)

≥6(%)

p

< 5(%)

≥5(%)

p

< 3.4(%)

≥3.4(%)

p

< 1.5(%)

≥1.5(%)

p

Age(y)

  

0.613

  

0.806

  

0.010

  

0.013

  

0.215

  < 60

187 (46.6)

6 (40.0)

 

177 (46.6)

16 (44.4)

 

190 (47.7)

3 (16.7)

 

157 (49.8)

36 (35.6)

 

156 (48.0)

37 (40.7)

 

  ≥ 60

214 (53.4)

9 (60.0)

 

203 (53.4)

20 (55.6)

 

208 (52.3)

15 (83.3)

 

158 (50.2)

65 (64.4)

 

169 (52.0)

54 (59.3)

 

Gender

  

0.507

  

0.606

  

0.721

  

0.271

  

0.349

 Male

322 (80.3)

11 (73.3)

 

303 (79.7)

30 (83.3)

 

318 (79.9)

15 (83.3)

 

256 (81.3)

77 (76.2)

 

257 (79.1)

76 (83.5)

 

 Female

79 (19.7)

4 (26.7)

 

77 (20.3)

6 (16.7)

 

80 (20.1)

3 (16.7)

 

59 (18.7)

24 (23.8)

 

68 (20.9)

15 (16.5)

 

Tumor length

  

0.117

  

0.015

  

0.127

  

0.067

  

< 0.001

  < 4

161 (40.1)

3 (20.0)

 

143 (37.6)

21 (58.3)

 

160 (40.2)

4 (22.2)

 

132 (41.9)

32 (31.7)

 

143 (44.0)

21 (23.1)

 

  ≥ 4

240 (59.9)

12 (80.0)

 

237 (62.4)

15 (41.7)

 

238 (59.8)

14 (77.8)

 

183 (58.1)

69 (68.3)

 

182 (56.0)

70 (76.9)

 

Tumor location

  

0.842

  

0.461

  

0.930

  

0.594

  

0.369

 Upper

32 (8.0)

1 (6.7)

 

29 (7.6)

4 (11.1)

 

32 (8.0)

1 (5.6)

 

27 (8.6)

6 (5.9)

 

29 (8.9)

4 (4.4)

 

 Middle

237 (59.1)

10 (66.7)

 

229 (60.3)

18 (50.0)

 

236 (59.3)

11 (61.1)

 

188 (59.7)

59 (58.4)

 

191 (58.8)

56 (61.5)

 

 Lower

132 (32.9)

4 (26.7)

 

122 (32.1)

14 (38.9)

 

130 (32.7)

6 (33.3)

 

100 (31.7)

36 (35.6)

 

105 (32.3)

31 (34.1)

 

Differentiation

  

0.555

  

0.634

  

0.372

  

0.299

  

0.050

Well-moderate

323 (80.5)

13 (86.7)

 

308 (81.1)

28 (77.8)

 

320 (80.4)

16 (88.9)

 

258 (81.9)

78 (77.2)

 

256 (78.8)

80 (87.9)

 

 Poor

78 (19.5)

2 (13.3)

 

72 (18.9)

8 (22.2)

 

78 (19.6)

2 (11.1)

 

57 (18.1)

23 (22.8)

 

69 (21.2)

11 (12.1)

 

pT category

  

0.475

  

0.679

  

0.467

  

0.355

  

0.051

 pT1

25 (6.2)

0 (0.0)

 

23 (6.1)

2 (5.6)

 

25 (6.3)

0 (0)

 

22 (7.0)

3 (3.0)

 

22 (6.8)

3 (3.3)

 

 pT2

100 (24.9)

2 (13.3)

 

92 (24.2)

10 (27.8)

 

99 (24.9)

3 (16.7)

 

80 (25.4)

22 (21.8)

 

88 (27.1)

14 (15.4)

 

 pT3

74 (18.5)

3 (20.0)

 

73 (19.2)

4 (11.1)

 

74 (18.6)

3 (16.7)

 

58 (18.4)

19 (18.8)

 

57 (17.5)

20 (22.0)

 

 pT4

202 (50.4)

10 (66.7)

 

192 (50.5)

20 (55.6)

 

200 (50.3)

12 (66.7)

 

155 (49.2)

57 (56.4)

 

158 (48.6)

54 (59.3)

 

pN category

  

0.280

  

0.443

  

0.001

  

0.007

  

< 0.001

 pN0

210 (52.4)

4 (26.7)

 

199 (52.4)

15 (41.7)

 

211 (53.0)

3 (16.7)

 

176 (55.9)

38 (37.6)

 

184 (56.6)

30 (33.0)

 

 pN1

141 (35.2)

8 (53.3)

 

132 (34.7)

17 (47.2)

 

139 (34.9)

10 (55.6)

 

105 (33.3)

44 (43.6)

 

111 (34.2)

38 (41.8)

 

 pN2

33 (8.2)

2 (13.3)

 

33 (8.7)

2 (5.6)

 

30 (7.5)

5 (27.8)

 

24 (7.6)

11 (10.9)

 

20 (6.2)

15 (16.5)

 

 pN3

17 (4.2)

1 (6.7)

 

16 (4.2)

2 (5.6)

 

18 (4.5)

0 (0.0)

 

10 (3.2)

8 (7.9)

 

10 (3.1)

8 (8.8)

 

TNM stage

  

0.361

  

0.773

  

0.075

  

0.070

  

< 0.001

 I

22 (5.5)

0 (0.0)

 

21 (5.5)

1 (2.8)

 

22 (5.5)

0 (0.0)

 

20 (6.3)

2 (2.0)

 

21 (6.5)

1 (1.1)

 

 II

125 (31.2)

3 (20.0)

 

117 (30.8)

11 (30.6)

 

126 (31.7)

2 (11.1)

 

102 (32.4)

26 (25.7)

 

112 (34.5)

16 (17.6)

 

 III

254 (63.3)

12 (80.0)

 

242 (63.7)

24 (66.7)

 

250 (62.8)

16 (88.9)

 

193 (61.3)

73 (72.3)

 

192 (59.1)

74 (81.3)

 

PC

  

0.994

  

0.400

  

0.928

  

0.088

  

0.575

 Yes

241 (60.1)

9 (60.0)

 

226 (59.5)

24 (66.7)

 

239 (60.1)

11 (61.1)

 

182 (57.8)

68 (67.3)

 

193 (59.4)

57 (62.6)

 

 No

160 (39.9)

6 (40.0)

 

154 (40.5)

12 (33.3)

 

159 (39.9)

7 (38.9)

 

133 (42.2)

33 (32.7)

 

132 (40.6)

34 (37.4)

 
  1. Abbreviations: CA carbohydrate antigen, CEA carcinoembryonic antigen, ESCC esophageal squamous cell carcinoma, PC postoperative chemotherapy, SCC-Ag squamous cell carcinoma antigen